Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Aptevo Therapeutics (APVO) Gross Profit (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Gross Profit for 5 consecutive years, with $2.9 million as the latest value for Q4 2019.

  • Quarterly Gross Profit changed N/A to $2.9 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Dec 2019, changed N/A year-over-year, with the annual reading at $12.5 million for FY2019, 5.43% up from the prior year.
  • Gross Profit hit $2.9 million in Q4 2019 for Aptevo Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $5.1 million in Q3 2019 to a low of -$2.4 million in Q2 2017.
  • Historically, Gross Profit has averaged $2.7 million across 5 years, with a median of $3.0 million in 2015.
  • Biggest YoY gain for Gross Profit was 432.3% in 2017; the steepest drop was 165.59% in 2017.
  • Year by year, Gross Profit stood at $3.0 million in 2015, then increased by 20.99% to $3.7 million in 2016, then grew by 16.56% to $4.3 million in 2017, then decreased by 21.23% to $3.4 million in 2018, then dropped by 14.53% to $2.9 million in 2019.
  • Business Quant data shows Gross Profit for APVO at $2.9 million in Q4 2019, $5.1 million in Q3 2019, and $1.4 million in Q2 2019.